ClinicalTrials.gg
CompletedNCT06029179Updated Feb 11, 2025

SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

An interventional study of sodium zirconium cyclosilicate (SZC) and sodium polystyrene sulfonate in Hyperkalemia, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.

Enrollment
13th of 27
120 · median 120
Started
2024
with 1 other
No phase
Only one
of the 27
Registered
24th of 27
by date
Lead sponsor
1 of 27
Alexandria University

Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 13th largest by enrollment, is one of 2 that started in 2024, is the only one with no phase, and was the 24th registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sodium zirconium cyclosilicate

sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, or all of them as a file.
02

Study summary

This study aims to compare the effects of Sodium Zirconium Cyclosilicate versus Sodium Polystyrene Sulfonate for treatment of hyperkalemia in patients undergoing regular hemodialysis.

Read the detailed description

Patients maintained on regular hemodialysis (HD) have a high risk of hyperkalemia (>5.0 mmol/l). Hyperkalemia is a critical medical condition that can result in arrhythmias and sudden cardiac death. Treatment of hyperkalemia in HD patients is challenging.

Therapeutic options for the treatment of hyperkalemia in HD population include potassium binding resins, such as sodium polystyrene sulfonate (SPS), patiromer, and sodium zirconium cyclosilicate. There is limited data about the use of these agents in HD.

03

Conditions studied

  • Hyperkalemia

Browse trials for

Keywords

  • Hyperkalemia
  • Hemodialysis
  • Sodium Zirconium Cyclosilicate
  • Sodium Polystyrene Sulfonate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥3 month of maintenance hemodialysis, 3 times per week for 4 hours.
  2. Adult patients with age above 18 years.
  3. baseline serum potassium level >5 mEq/L.

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal diseases (constipation, bleeding, Hx of endoscopy, chronic diarrhea or diarrhea in the past month, malabsorption, GIT surgery, ischemic colitis, necrosis, perforation, ....).
  2. Breast feeding or pregnancy.
  3. Patients who receive medications to treat hyperkalemia 2 weeks before study.
  4. myocardial infarction, acute coronary syndrome, stroke, seizure, or thromboembolic event within 8 weeks before study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Group A

    60 patients will receive sodium zirconium cyclosilicate (SZC)

    Drug: sodium zirconium cyclosilicate (SZC)

  • Active comparator
    Group B

    60 patients will receive sodium polystyrene sulfonate

    Drug: sodium polystyrene sulfonate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in serum potassium

    By assessing serum K at baseline, 24 hrs after first dose, then weekly after the long interdialytic interval

    Time frame: 8 weeks

Secondary outcomes

  1. Change in interdialytic weight

    By assessing change in interdialytic weight

    Time frame: 8 weeks

  2. Gastrointestinal side effects

    By reporting any GIT SE

    Time frame: 8 weeks

  3. Change in Blood pressure

    systolic and diastolic Blood pressure change

    Time frame: 8 weeks

  4. Serious adverse events

    By reporting any serious adverse events.

    Time frame: 8 weeks

07

Study locations

1 site
  • Faculty of Medicine, Aexandria University
    Alexandria, 21526, Egypt
08

References and documents

Publications

  • Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB. Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study. Am J Nephrol. 2016;44(3):179-86. doi: 10.1159/000448341. Epub 2016 Sep 3. PubMed 27592170 ↗
  • Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schottker B. Association of Abnormal Serum Potassium Levels with Arrhythmias and Cardiovascular Mortality: a Systematic Review and Meta-Analysis of Observational Studies. Cardiovasc Drugs Ther. 2018 Apr;32(2):197-212. doi: 10.1007/s10557-018-6783-0. PubMed 29679302 ↗
  • Beccari MV, Meaney CJ. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. Core Evid. 2017 Mar 23;12:11-24. doi: 10.2147/CE.S129555. eCollection 2017. PubMed 28356904 ↗
  • Fried L, Kovesdy CP, Palmer BF. New options for the management of chronic hyperkalemia. Kidney Int Suppl (2011). 2017 Dec;7(3):164-170. doi: 10.1016/j.kisu.2017.09.001. Epub 2017 Nov 17. PubMed 30675431 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Oct 2024, 9 months.

Of 16 interventional studies with no phase under Hyperkalemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 8, 2023
StartActual
Jan 15, 2024
Primary completionActual
Oct 15, 2024
CompletionActual
Dec 15, 2024
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029179
Responsible party
Mohamed Mamdouh Mahmoud Mohamed Elsayed , MD (Lecturer, Alexandria University) — Principal investigator
First posted
Sep 8, 2023
Start date
Jan 15, 2024
Primary completion
Oct 15, 2024
Completion
Dec 15, 2024
Last update
Feb 11, 2025

Study contacts

Mohamed Mamdouh Elsayed, MD
principal investigator · lecturer
Marwa Ahmed Abdelrahman, MD
study chair · consultant
Mohamed Aly Abdelhalim, MD
study chair · Lecturer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sodium zirconium cyclosilicate · Polystyrene sulfonic acid

Start the discussion